Defining sporadic Creutzfeldt-Jakob disease strains and their transmission properties

The biological determinants of the phenotypic variation in sporadic Creutzfeldt-Jakob disease (sCJD) are unknown. To categorize sCJD cases, the prion protein (PrP) codon 129 genotype and the biochemical characteristics of the disease-associated form of PrP (PrPSc) can be combined to form six subgroups (MM1, MM2, MV1, MV2, VV1, and VV2). This classification largely correlates with the known variation in the clinical and pathological features of sCJD, with the MM1 and MV1 cases representing the “classic” phenotype of sCJD. To address how this classification relates to different strains of sCJD we have inoculated each subgroup of sCJD to a panel of mice expressing different forms of the human PRNP gene (129MM, 129VV, and 129MV). We have established that all subtypes are transmissible to at least one genotype of mouse, and both agent and host factors determine transmission efficiency and the form of PrPSc deposited in the brain. Moreover, we have identified four distinct strains of sCJD using our in vivo strain typing panel.

[1]  T. Pinheiro,et al.  Low Density Subcellular Fractions Enhance Disease-specific Prion Protein Misfolding , 2010, The Journal of Biological Chemistry.

[2]  I. Mcconnell,et al.  Transmissions of variant Creutzfeldt-Jakob disease from brain and lymphoreticular tissue show uniform and conserved bovine spongiform encephalopathy-related phenotypic properties on primary and secondary passage in wild-type mice. , 2009, The Journal of general virology.

[3]  J. Hauw,et al.  Beyond PrPres Type 1/Type 2 Dichotomy in Creutzfeldt-Jakob Disease , 2008, PLoS pathogens.

[4]  John Collinge,et al.  A General Model of Prion Strains and Their Pathogenicity , 2007, Science.

[5]  L. Minati,et al.  Conversion of the BASE Prion Strain into the BSE Strain: The Origin of BSE? , 2007, PLoS pathogens.

[6]  R. Nonno,et al.  Efficient Transmission and Characterization of Creutzfeldt–Jakob Disease Strains in Bank Voles , 2006, PLoS pathogens.

[7]  J. Ironside,et al.  Predicting susceptibility and incubation time of human-to-human transmission of vCJD , 2005, The Lancet Neurology.

[8]  L. Breydo,et al.  The presence of valine at residue 129 in human prion protein accelerates amyloid formation , 2005, FEBS letters.

[9]  J. Collinge,et al.  Human Prion Protein with Valine 129 Prevents Expression of Variant CJD Phenotype , 2004, Science.

[10]  A. Aguzzi,et al.  Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. , 2004, Brain : a journal of neurology.

[11]  J. Ironside,et al.  Prion protein heterogeneity in sporadic but not variant Creutzfeldt–Jakob disease: U.K. cases 1991–2002 , 2004, Annals of neurology.

[12]  P. Disterer,et al.  Methionine 129 Variant of Human Prion Protein Oligomerizes More Rapidly than the Valine 129 Variant , 2004, Journal of Biological Chemistry.

[13]  S. Mohri,et al.  Humanized knock-in mice expressing chimeric prion protein showed varied susceptibility to different human prions. , 2003, The American journal of pathology.

[14]  Y. Agid,et al.  Distribution of codon 129 genotype in human growth hormone-treated CJD patients in France and the UK , 2003, The Lancet.

[15]  K. Stefánsson,et al.  Prion susceptibility and protective alleles exhibit marked geographic differences , 2003, Human mutation.

[16]  H. Budka,et al.  Molecular classification of sporadic Creutzfeldt-Jakob disease. , 2003, Brain : a journal of neurology.

[17]  S. Prusiner,et al.  Abbreviated incubation times for human prions in mice expressing a chimeric mouse–human prion protein transgene , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Collinge,et al.  BSE prions propagate as either variant CJD‐like or sporadic CJD‐like prion strains in transgenic mice expressing human prion protein , 2002, The EMBO journal.

[19]  J. Ironside,et al.  Neuropathology of variant Creutzfeldt-Jakob disease. , 2002, Acta neurobiologiae experimentalis.

[20]  S. Itohara,et al.  Follicular dendritic cell of the knock-in mouse provides a new bioassay for human prions. , 2002, Biochemical and biophysical research communications.

[21]  L. McShane,et al.  Iatrogenic Creutzfeldt–Jakob disease at the millennium , 2000, Neurology.

[22]  B. Ghetti,et al.  Genetic influence on the structural variations of the abnormal prion protein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P Brown,et al.  Classification of sporadic Creutzfeldt‐Jakob disease based on molecular and phenotypic analysis of 300 subjects , 1999, Annals of neurology.

[24]  A. Alpérovitch,et al.  Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease , 1999, The Lancet.

[25]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[26]  D. Dormont,et al.  Genotype at codon 129 and susceptibility to Creutzfeldt-Jakob disease , 1998, The Lancet.

[27]  S. Cousens,et al.  Transmissions to mice indicate that ‘new variant’ CJD is caused by the BSE agent , 1997, Nature.

[28]  Andrew F. Hill,et al.  The same prion strain causes vCJD and BSE , 1997, Nature.

[29]  J Q Trojanowski,et al.  Molecular basis of phenotypic variability in sporadc creudeldt‐jakob disease , 1996, Annals of neurology.

[30]  P. Brown,et al.  Human spongiform encephalopathy: The national institutes of health series of 300 cases of experimentally transmitted disease , 1994, Annals of neurology.

[31]  J. Bell,et al.  Neuropathology of spongiform encephalopathies in humans. , 1993, British medical bulletin.

[32]  A. Aguzzi,et al.  Mice devoid of PrP are resistant to scrapie , 1993, Cell.

[33]  P Brown,et al.  Fatal familial insomnia and familial Creutzfeldt-Jakob disease: disease phenotype determined by a DNA polymorphism. , 1992, Science.

[34]  S. Prusiner.  Novel proteinaceous infectious particles cause scrapie. , 1982, Science.

[35]  H. Fraser,et al.  The sequential development of the brain lesion of scrapie in three strains of mice. , 1968, Journal of comparative pathology.

[36]  J. Hauw,et al.  Beyond PrP res type 1/type 2 dichotomy in Creutzfeldt-Jakob disease. , 2008, PLoS pathogens.

[37]  F. Wiseman.  Glycosylation of PrP and the transmissible spongiform encephalopathies species barrier , 2006 .